Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey R Infante

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Cancer Treatment Reviews|March 28, 2016
Targeting CDK4/6 in patients with cancerErika Hamilton, Jeffrey R Infante
The Lancet. Oncology|July 20, 2014
Combined inhibition of BRAF and MEK in melanoma patientsJeffrey R Infante, Charles Swanton
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2015
Molecular Pathways: Fatty Acid SynthaseSuzanne F Jones, Jeffrey R Infante
The Lancet. Oncology|July 2, 2013
PARP inhibitors: pitfalls and promisesJeffrey R Infante, Howard A Burris
Drugs|October 26, 2014
Clinical impact of checkpoint inhibitors as novel cancer therapiesKent Shih, Hendrik-Tobias Arkenau, Jeffrey R Infante
Pharmacology & Therapeutics|September 22, 2014
Targeting PI3 kinase in cancerTodd M Bauer, Manish R Patel, Jeffrey R Infante
Cancer Biology & Therapy|November 15, 2007
Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancerHiroyuki Matsubayashi, Jeffrey R Infante, Jordan Winter, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumorsKathleen Moore, Jeffrey R Infante, Monette M Cotreau, et al.
Cancer Investigation|June 24, 2011
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinomaJohn D Hainsworth, Jeffrey R Infante, David R Spigel, et al.
Melanoma Research|August 24, 2013
Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research ConsortiumRalph J Hauke, Jeffrey R Infante, Mark S Rubin, et al.
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Cancer Treatment Reviews|March 28, 2016
Targeting CDK4/6 in patients with cancerErika Hamilton, Jeffrey R Infante
The Lancet. Oncology|July 20, 2014
Combined inhibition of BRAF and MEK in melanoma patientsJeffrey R Infante, Charles Swanton
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2015
Molecular Pathways: Fatty Acid SynthaseSuzanne F Jones, Jeffrey R Infante
The Lancet. Oncology|July 2, 2013
PARP inhibitors: pitfalls and promisesJeffrey R Infante, Howard A Burris
Drugs|October 26, 2014
Clinical impact of checkpoint inhibitors as novel cancer therapiesKent Shih, Hendrik-Tobias Arkenau, Jeffrey R Infante
Pharmacology & Therapeutics|September 22, 2014
Targeting PI3 kinase in cancerTodd M Bauer, Manish R Patel, Jeffrey R Infante
Cancer Biology & Therapy|November 15, 2007
Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancerHiroyuki Matsubayashi, Jeffrey R Infante, Jordan Winter, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumorsKathleen Moore, Jeffrey R Infante, Monette M Cotreau, et al.
Cancer Investigation|June 24, 2011
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinomaJohn D Hainsworth, Jeffrey R Infante, David R Spigel, et al.
Melanoma Research|August 24, 2013
Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research ConsortiumRalph J Hauke, Jeffrey R Infante, Mark S Rubin, et al.
Pageof 13